Christoph J. Ackermann

Thun, BE, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment.

Self-reported financial difficulties of colorectal cancer patients 1 year after start of treatment.

Journal: ESMO open

Published: December 23, 2024

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 03, 2023

Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis.

Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis.

Journal: International journal of cancer

Published: February 07, 2023

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.

A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.

Journal: Scientific reports

Published: October 04, 2022

From open Ivor Lewis esophagectomy to a hybrid robotic-assisted thoracoscopic approach: a single-center experience over two decades.

From open Ivor Lewis esophagectomy to a hybrid robotic-assisted thoracoscopic approach: a single-center experience over two decades.

Journal: Langenbeck's archives of surgery

Published: November 10, 2021

Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

Price trends of reimbursed oncological drugs in Switzerland in 2005-2019: A descriptive analysis.

Journal: PloS one

Published: September 22, 2021

First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.

First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.

Journal: Drugs

Published: September 28, 2020

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.

Journal: ESMO open

Published: August 20, 2020

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: March 05, 2020

Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform.

Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform.

Journal: European radiology

Published: February 26, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026